Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Akbeta
2. Apo Levobunolol
3. Apo-levobunolol
4. Apolevobunolol
5. Betagan
6. Levobunolol
7. Novo Levobunolol
8. Novo-levobunolol
9. Novolevobunolol
10. Pms Levobunolol
11. Pms-levobunolol
12. Pmslevobunolol
13. Ratio Levobunolol
14. Ratio-levobunolol
15. Ultracortenol
16. Vistagan
17. W 7000a
18. W-7000a
19. W7000a
1. Akbeta
2. Betagan
3. Levobunolol Hcl
4. 27912-14-7
5. Levobunolol (hydrochloride)
6. Levobunolol.hcl
7. Vistagan
8. W 7000a
9. (-) -levobunolol Hydrochloride
10. L-bunolol Hydrochloride
11. Chebi:6439
12. Nsc-759158
13. W-7000a
14. Dsstox_cid_777
15. Dsstox_rid_75784
16. Dsstox_gsid_20777
17. (-)-3,4-dihydro-5-(3-(tert-butylamino)-2-hydroxypropoxy)-1(2h)-naphthalenone Hydrochloride
18. (-)-5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone Hydrochloride
19. O90s49ldhh
20. Levobunolol Hydrochloride [usan]
21. Ncgc00016801-01
22. Levobunolol, Hydrochloride
23. Cas-27912-14-7
24. Ent-levobunolol,hydrochloride
25. Prestwick_167
26. Betagan (tn)
27. Levobunolol Monohydrochloride
28. Schembl42262
29. Mls002154030
30. Chembl1201177
31. Dtxsid6020777
32. Hms1570j15
33. 5-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2h-naphthalen-1-one;hydrochloride
34. Hy-b1035
35. Tox21_110617
36. Levobunolol Hydrochloride (jan/usp)
37. Levobunolol Hydrochloride [mi]
38. Tox21_110617_1
39. Ccg-220847
40. Cs-4554
41. Levobunolol Hydrochloride [jan]
42. Levobunolol Hydrochloride [mart.]
43. Levobunolol Hydrochloride [vandf]
44. Ncgc00016801-05
45. 5-({(2s)-3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydronaphthalen-1(2h)-one Hydrochloride
46. Levobunolol Hydrochloride [usp-rs]
47. Levobunolol Hydrochloride [who-dd]
48. Smr001233357
49. D01025
50. Levobunolol Hydrochloride [orange Book]
51. Levobunolol Hydrochloride [usp Monograph]
52. Q27107207
53. (-)-(s)-5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone Hydrochloride
54. (2s)-n-(tert-butyl)-2-hydroxy-3-[(5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]propan-1-aminium Chloride
55. 1(2h)-naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, Hydrochloride, (-)-(s)
56. 5-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2h)-one Hydrochloride
| Molecular Weight | 327.8 g/mol |
|---|---|
| Molecular Formula | C17H26ClNO3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 327.1601214 g/mol |
| Monoisotopic Mass | 327.1601214 g/mol |
| Topological Polar Surface Area | 58.6 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 350 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 6 | |
|---|---|
| Drug Name | Akbeta |
| Active Ingredient | Levobunolol hydrochloride |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 0.25% |
| Market Status | Prescription |
| Company | Akorn |
| 2 of 6 | |
|---|---|
| Drug Name | Betagan |
| Drug Label | BETAGAN (levobunolol hydrochloride ophthalmic solution, USP) sterile is a noncardioselective beta-adrenoceptor blocking agent for ophthalmic use. The solution is colorless to slightly light yellow in appearance with an osmolality range of 250-360 m... |
| Active Ingredient | Levobunolol hydrochloride |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 0.25% |
| Market Status | Prescription |
| Company | Allergan |
| 3 of 6 | |
|---|---|
| Drug Name | Levobunolol hydrochloride |
| PubMed Health | Levobunolol (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | BETAGAN (levobunolol hydrochloride ophthalmic solution, USP) sterile is a noncardioselective beta-adrenoceptor blocking agent for ophthalmic use. The solution is colorless to slightly light yellow in appearance with an osmolality range of 250-360 m... |
| Active Ingredient | Levobunolol hydrochloride |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 0.25% |
| Market Status | Prescription |
| Company | Falcon Pharms; Bausch And Lomb |
| 4 of 6 | |
|---|---|
| Drug Name | Akbeta |
| Active Ingredient | Levobunolol hydrochloride |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 0.25% |
| Market Status | Prescription |
| Company | Akorn |
| 5 of 6 | |
|---|---|
| Drug Name | Betagan |
| Drug Label | BETAGAN (levobunolol hydrochloride ophthalmic solution, USP) sterile is a noncardioselective beta-adrenoceptor blocking agent for ophthalmic use. The solution is colorless to slightly light yellow in appearance with an osmolality range of 250-360 m... |
| Active Ingredient | Levobunolol hydrochloride |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 0.25% |
| Market Status | Prescription |
| Company | Allergan |
| 6 of 6 | |
|---|---|
| Drug Name | Levobunolol hydrochloride |
| PubMed Health | Levobunolol (Into the eye) |
| Drug Classes | Antiglaucoma |
| Drug Label | BETAGAN (levobunolol hydrochloride ophthalmic solution, USP) sterile is a noncardioselective beta-adrenoceptor blocking agent for ophthalmic use. The solution is colorless to slightly light yellow in appearance with an osmolality range of 250-360 m... |
| Active Ingredient | Levobunolol hydrochloride |
| Dosage Form | Solution/drops |
| Route | Ophthalmic |
| Strength | 0.5%; 0.25% |
| Market Status | Prescription |
| Company | Falcon Pharms; Bausch And Lomb |
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
Adrenergic beta-Antagonists
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A Levobunolol HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Levobunolol HCl, including repackagers and relabelers. The FDA regulates Levobunolol HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Levobunolol HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Levobunolol HCl supplier is an individual or a company that provides Levobunolol HCl active pharmaceutical ingredient (API) or Levobunolol HCl finished formulations upon request. The Levobunolol HCl suppliers may include Levobunolol HCl API manufacturers, exporters, distributors and traders.
Levobunolol HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Levobunolol HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Levobunolol HCl GMP manufacturer or Levobunolol HCl GMP API supplier for your needs.
A Levobunolol HCl CoA (Certificate of Analysis) is a formal document that attests to Levobunolol HCl's compliance with Levobunolol HCl specifications and serves as a tool for batch-level quality control.
Levobunolol HCl CoA mostly includes findings from lab analyses of a specific batch. For each Levobunolol HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Levobunolol HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Levobunolol HCl EP), Levobunolol HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Levobunolol HCl USP).
LOOKING FOR A SUPPLIER?
